metadata toggle
Clinical particulars
Target Species
Horses and other equines.
Indications for use
For the treatment and control of adult and immature roundworms of the gastro-intestinal tract in horses and other equines.
The product is also effective for the treatment and control of encysted mucosal 3rd and 4th stage small strongyle larvae and is also effective against encysted inhibited 3rd stage small strogyle larvae in the mucosa.
The product is also effective in controlling other immature and mature roundworms including large redworm (Strongylus edentatus and Strongylus vulgaris) and migrating large redworm, Ascarids (Parascaris equorum), Oxyuris and Strongyloides species and benzimidazole susceptible adult and immature small strongyles (Cyathostomes).
The product also has an ovicidal effect on nematode eggs.
Contraindications
None known.
Special warnings for each target species
Care should be taken to avoid the following practices because they increase the risk of development of resistance and could ultimately result in ineffective therapy:
∙ Too frequent and repeated use of anthelmintics from the same class, over an extended period of time.
∙ Under dosing, which may be due to underestimation of body weight, misadministration of the product, or lack of calibration of the dosing device (if any).
Suspected clinical cases of resistance to anthelmintics should be further investigated using appropriate tests (e.g. Faecal Egg Count Reduction Test). Where the results of the test(s) strongly suggest resistance to a particular anthelmintic, an anthelmintic belonging to another pharmacological class and having a different mode of action should be used.
Resistance to fenbendazole has been reported in cyathostomes in horses. Therefore the use of this product should be based on local (regional, farm) epidemiological information about susceptibility of nematodes and recommendations on how to limit further selection for resistance to anthelmintics.
Special precautions for use
Assess bodyweight as accurately as possible before calculating the dosage.
Intensive use or misuse of anthelmintics can give rise to resistance. To reduce this risk, dosing programmes should be discussed with your veterinary surgeon.
Operator warnings
Direct contact with the skin should be kept to a minimum. Wear suitable protective clothing including impermeable rubber gloves.
Wash hands after use.
Adverse Reactions
None known.
Use during pregnancy or lactation
Pregnant mares and young foals may also be safely treated with fenbendazole at therapeutic dosage levels.
Interactions
None known.
Amounts to be administered and administration route
For oral administration.
No dietary control is required before or after treatment.
For the treatment and control of migrating and tissue larval stages of large strongyles, encysted mucosal 3rd and 4th stage small strongyle larvae and encysted inhibited 3rd stage small strongyle larvae in the mucosa administer 5 ml of the product per 65 kg bodyweight daily for 5 days (= 7.5 mg fenbendazole/kg bodyweight daily for 5 days).
The product can be easily administered by mixing with grain or concentrate feed. The full daily dosage must be given as one administration.
To ensure administration of a correct dose, body weight should be determined as accurately as possible; accuracy of the dosing device should be checked.
Recommended dosing programme
Treatment of encysted inhibited and encysted mucosal dwelling larvae should be performed in the autumn (ideally late October/November) and again in the Spring (ideally in February). However, for horses that fail to maintain condition or bought-in horses with unknown worming history, the treatment can be given at any time of the year.
Shake container before use.
Treatment with this product should form part of an integrated worming plan. Consult with your supplier for advice regarding wormers to use throughout the year.
Overdose
Benzimidazoles have a wide margin of safety.
Withdrawal periods
Not to be used in horses intended for human consumption.
Treated horses may never be slaughtered for human consumption.
The horse must have been declared as not intended for human consumption under national horse passport legislation.